Ames BN, Durston WE, Yamasaki E. & Lee FDCarcinogens are mutagens: a single test system combining liver homogenates for activation and bacteria for detection. Proceedings of the National Academy of Science USA1973; 70: 2281-5.
2.
Ashby JA & Tennent RWDefinitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTPMutation Research1991; 257: 229-306.
3.
Nishizuka Y.Phospholipid degradation and signal translation for protein phosphorylationTrends in Biochemical Science1983; 8: 13-16.
4.
Li JJ & Li SAEstrogen carcinogenesis in hamster tissues: a critical review. Endocrine Reviews1990; 11: 524-31.
5.
Nebert DWThe Ah locus: Genetic differences in toxicity, cancer, mutation and birth defects. CRC Critical Reviews in Toxicology, 1989; 20: 153-74.
6.
Issemann I. & Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature1990; 347: 645-50.
7.
Reddy JK & Lalwani NDCarcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Critical Reviews in Toxicology1983; 12: 1-58.
8.
Lock EA, Mitchell AM & Elcombe CRBiochemical mechanisms of induction of hepatic peroxisome proliferation Annual Reviews in Pharmacology and Toxicology1989 ; 29: 145-63.
9.
Moody DE, Reddy JK, Lake BG, Popp JA & Reese DHPeroxisome proliferation and nongenotoxic carcinogenesis: commentary on a symposium. Fundamentals of Applied Toxicology1991; 16: 223-48.
10.
Hess R., Staubli W & Riess W.Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the ratNature1965; 208: 856-8.
11.
Reddy JK, Rao MS, Azarnoff DL & Sell S.Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14,643), in rat and mouse liver. Cancer Research1979; 39: 152-61.
12.
Styles JA, Kelly M., Pritchard NR & Elcombe CRA species comparison of acute hyperplasia induced by the peroxisome proliferator methylclofenapate: involvement of the bi-nucleated hepatocyte . Carcinogenesis1988; 9: 1647-55.
13.
Lazarow PB & de Duve C.A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proceedings of the National Academy of Science USA, 1976; 73: 2043-6.
14.
Osumi T. & Hashimoto T.Enhancement of fatty acyl-CoA oxidizing activity in rat liver peroxisomes by di-(2-ethylhexyl)phthalate. Journal of Biochemistry1978; 83: 1361-5.
15.
Orton TC & Parker GLThe effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid. Drug Metabolism Dispos. 1982; 10: 110-15.
16.
Reddy JK, Goel SK, Nemali MR et al. Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proceedings of the National Academy of Science USA1986; 83: 1747-51.
17.
Hardwick JP , Song BJ, Huberman E. & Gonzalez FJIsolation, complementary DNA sequence, and regulation of rat hepatic lauric acid omega-hydroxylase (cytochrome P-450LA omega). Identification of a new cytochrome P-450 gene family. Journal of Biological Chemistry1987 ; 262: 801-10.
18.
Hertz R., Aurbach R., Hashimoto T. & Bar-Tana J.Thyromimetic effect of peroxisomal proliferators in rat liver. Biochemical Journal1991; 274: 745-51.
19.
Rao MS, Lalwani ND & Reddy JKSequential histologic study of rat liver during peroxisome proliferator (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)-acetic acid (Wy-14,643)-induced carcinogenesis. Journal of the National Cancer Institute1984; 73: 983-90.
20.
Marsman DS, Cattley RC, Conway JG & Popp JARelationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid (Wy-14,643) in rats. Cancer Research1988; 48: 6739-44.
21.
Kluwe WM, Haseman JK, Douglas JF & Huff JEThe carcinogenicity of dietary di(2-ethylhexyl) phthalate (DEHP) in Fischer 344 rats and B6C3F1 mice. Journal of Toxicology and Environmental Health1982; 10: 797-815.
22.
Kasai H., Okadi Y., Nishimura S., Rao MS & Reddy JKFormation of 8-hydroxydcoyguanosinc in liver DNA of rats following long-term exposure to a peroxisome proliferator. Cancer Research1989; 49: 2603-5.
23.
Randerath E. , Randerath K., Reddy R., Danna TF, Rao MS & Reddy JKInduction of rat livcr DNA alternations by chronic administration of peroxisome proliferators as detected by 32P-postlabeling . Mutation Research1991; 247: 65-76.
24.
Conway JG, Tomaszewski KE, Olson MJ et al. Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. Carcinogenesis1989; 10: 513-19.
25.
Cattley RC & Popp JADifferences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver. Cancer Research1989; 49: 3246-51.
26.
Green S. & Chambon P.Nuclear receptors enhance our understanding of transcription regulation . Trends in Genetics1988; 4: 309-14.
Karin M., Haslinger A., Holtgreve A. et al. Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-IIA gene. Nature1984; 308: 513-19.
30.
Martinez E. , Givel F. & Wahli W.The estrogen-responsive element as an inducible enhancer: DNA sequence requirements and conversion to a glucocorticoid-responsive element. EMBO Journal1987; 6: 3719-27.
31.
Akerblom IE , Slater EP, Beato M., Baxter JD & Mellon PLNegative regulation by glucocorticoids through interference with a cAMP responsive enhancer. Science1988; 241: 350-3.
32.
Glass CK, Holloway JM, Devary OV & Rosenfeld MGThe thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements . Cell1988; 54: 313-23.
33.
Glass CK, Lipkin SM, Devary OV & Rosenfeld MGPositive and negative regulation of gene transcription by a retinoic acid-thyroid hormone receptor heterodimer. Cell1989; 59: 697-708.
34.
Schwabe Jwr , Neuhaus D. & Rhodes D.Solution structure of the DNA-binding domain of the oestrogen receptor. Nature1990; 348: 458-61.
35.
Mader S., Kumar V., de Verneuil H. & Chambon P.Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element. Nature1989; 338: 271-4.
36.
Umesono K. & Evans RMDeterminants of target gene specificity for steroid/thyroid hormone receptors . Cell1989; 57: 1139-46.
37.
Danielsen M. , Hinck L. & Ringold GMTwo amino acids within the knuckle of the first zinc finger specify DNA response element activation by the glucocorticoid receptor. Cell1989; 57: 1131-8.
38.
Nemali MR , Usuda N., Reddy MK et al. Comparison of constitutive and inducible levels of expression of peroxisomal beta-oxidation and catalase genes in liver and extra-hepatic tissues of rat. Cancer Research1988; 48: 5316-24.
39.
Power RF, Lydon JP, Conneely OM & O'Malley BWDopamine activation of an orphan of the steroid receptor superfamily . Science1991; 252: 1546-8.
40.
Alvares K. , Carrillo A., Yuan PM et al. Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family . Proceedings of the National Academy of Science USA1990; 87: 5293-7.
41.
Lake BG, Gray Tjb, Pels Rifcken WR, Beamand JA & Gangolli SDThe effect of hypolipidaemic agents on peroxisomal beta-oxidation and mixed-function oxidase activities in primary cultures of rat hepatocytes . Relationship between induction of palmitoyl-CoA oxidation and lauric acid hydroxylation. Xenobiotica1984; 14: 269-76.
42.
Lake BG, Lewis Dfv & Gray Tjb.Structure-activity relationships for hepatic peroxisome proliferation . Archives of Toxicology1988; 12 (suppl): 217-24.
43.
Eacho PI, Foxworthy PS, Dillard RD et al. Induction of peroxisomal beta-oxidation in the rat liver in vivo and in vitro by tetrazole-substituted acetophenones: structure-activity relationships. Toxicology and Applied Pharmacology1989; 100: 177-84.
44.
Flatmark T. , Nilsson A., Kvannes J. et al. On the mechanism of induction of the enzyme systems for peroxisomal beta-oxidation of fatty acids in rat liver by diets rich in partially hydrogenated fish oil. Biochemica Biophysical Acta1988; 962: 122-30.
45.
Nilsson A., Arey H., Pedersen JI & Christiansen ENThe effect of high-fat diets on microsomal lauric acid hydroxylation in rat liver. Biochemica Biophysica Acta1986; 879: 209-14.
46.
Frenkel RA, Slaughter CA, Orth K. et al. Peroxisome proliferation and induction of peroxisomal enzymes in mouse and rat liver by dehydroepiandrosterone feeding. Journal of Steroid Biochemistry1990; 35: 333-42.
47.
Kase BF, Prydz K., Björkhem I. & Pedersen JIIn-vitro formation of bile acids from di- and trihydroxy-5 betacholestanoic acid in human liver peroxisomes. Biochemica Biophysica Acta1986; 877: 37-42.
48.
de The H., Vivanco-Riuz MM, Tiollais P., Stunnenberg H. & Dejean A.Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature1990; 343: (177-80).
49.
Vasios G., Mader S., Gold JD et al. The late retinoic acid induction of laminin B 1 gene transcription involves RAR binding to the responsive element. EMBO Journal1991; 10: 1149-58.
50.
Osumi T., Ishii N., Miyazawa S. & Hashimoto T.Isolation and structural characterization of the rat acyl-CoA oxidase gene . Journal of Biologial Chemistry1987 ; 262: 8138-43.
51.
Tugwood JD, Issemann I., Anderson RG, Bundell, K., McPheat, W. & Green S.The mouse peroxisome proliferator activated receptor recognizes a response element in the rat acyl CoA oxidase gene promoter. (submitted).
52.
Osumi T., Wen JK & Hashimoto T.Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of the rat acyl CoA oxidase gene. Biochemistry Biophysics Research Communications1991; 175: 866-71.
53.
Gerbacht U. , Bursch W., Kraus P. et al. Effects of hypolipidemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver. Carcinogenesis1990; 11: 617-24.
54.
Bentley P., Bieri F., Muakkassah-Kelly S., Staubli W. & Waechter F.Mechanisms of tumour induction by peroxisome proliferators. Archives of Toxicology1988; 12 (suppl.): 240-7.
55.
Cherkaoui-Malki M., Lone YC, Corral-Debrinski M. & Latruffe N.Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators . Biochemistry Biophsyics Research Communications1990; 173: 855-61.
56.
Gupta C., Hattori A. & Shinozuka H.Suppression of EGF binding in rat liver by the hypolipidemic peroxisome proliferators, 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio-(N-beta-hydroxyethyl) acetamide and di(2-ethylhexyl) phthalate. Carcinogenesis1988; 9: 167-9.
57.
Elcombe CR & Mitchell AMPeroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): species differences and possible mechanisms. Environmental Health Perspectives1986; 70: 211-19.
58.
Eacho PI, Foxworthy PS, Johnson WD, Hoover DM & White SLHepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicology and Applied Pharmacology1986; 83: 430-7.
59.
Lake BG, Evans JG, Gray Tjb, Korosi SA & North CJComparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicology and Applied Pharmacology1989; 99: 148-60.
60.
Blumcke S., Schwartzkopff W., Lobeck H. et al. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis1983; 46: 105-16.
61.
Hanefeld M. , Kemmer C. & Kadner E.Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis1983; 46: 239-46.
62.
U.S. Environmental Protection Agency. Guidelines for carcinogenic risk assessment. Federal Register1986; 51: 33992-4003.
63.
Roberts L.Dioxin risks revisited. Science1991 ; 251: 624-6.
